about
New viruses for cancer therapy: meeting clinical needsNew trends in molecular and cellular biomarker discovery for colorectal cancerTherapeutic Targeting of TelomeraseThe mutational landscape of hepatocellular carcinomaTelomerase reverse transcriptase moonlights: Therapeutic targets beyond telomeraseThe impact of cellular senescence in cancer therapy: is it true or not?Molecular regulation of telomerase activity in agingTherapeutic targeting of replicative immortalityStructural basis for protein-RNA recognition in telomeraseThe Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating PeptideNanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive systemStructure of active dimeric human telomerase.Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysisCell proliferation in the presence of telomeraseInhibition of human dyskerin as a new approach to target ribosome biogenesisProperties of protein drug target classesEfforts to make and apply humanized yeastSilencing disease genes in the laboratory and the clinicPrinciples of cancer therapy: oncogene and non-oncogene addictionDesigning a broad-spectrum integrative approach for cancer prevention and treatment.Telomere dynamics in human cells reprogrammed to pluripotency.HPV16 E7 protein and hTERT proteins defective for telomere maintenance cooperate to immortalize human keratinocytesTelomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.Association between the telomerase reverse transcriptase (TERT) rs2736098 polymorphism and cancer risk: evidence from a case-control study of non-small-cell lung cancer and a meta-analysis.Dynamic telomerase gene suppression via network effects of GSK3 inhibitionThe effects of telomerase inhibition on prostate tumor-initiating cells.Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer.Telomere-dependent and telomere-independent origins of endogenous DNA damage in tumor cells.Telomeres and telomerase: from discovery to clinical trials.Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cellsTargeting telomerase: T-cell friendly fire.Sensing telomerase: From in vitro detection to in vivo imaging.In vitro anti-telomerase activity of novel lycopene-loaded nanospheres in the human leukemia cell line K562.Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways.Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics.Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA.Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artTelomerase trafficking and assembly in Xenopus oocytes.Telomerase enzymatic component hTERT shortens long telomeres in human cells.
P2860
Q24567699-6BA1EB5F-BC92-410B-BA1D-9490D7006E3CQ26739049-86322EC3-732E-4E85-9B54-7C7CD0A7B1EBQ26741736-0D778962-B10D-4A89-9697-DB4BA74B2E24Q26777478-99B43B06-4D20-42C8-88FF-E28E082B24BBQ26786613-24A9664D-0095-4894-B18A-8031C58496EDQ26825221-019A22F9-2E1C-4A40-933E-24C7F6DCE337Q26861714-2D8CEC05-6CEB-4C50-BFA7-EDC4A6B69EE6Q27027457-5FF403AB-5F33-411B-B4D4-F9DD481FD134Q27683630-64373EC6-0A70-4F63-9730-EA39DF91F2D4Q28076133-1B3898F1-3FBC-46AA-BAE5-16AEAE91D887Q28079367-757048A3-BF3F-4482-82D9-10C9C97BE795Q28115347-FD9328A8-CA36-4682-8D56-98301D2E451CQ28265076-FB39777A-AC0A-41B1-A047-21200F43C7BCQ28474871-D5694BA7-3E89-4BE5-94A4-74FBDDE44014Q28540640-A51DB27B-741F-4AFF-8E8A-8B761C8AD29DQ28545197-F060D749-CF6A-40BB-9F35-78C07BB04466Q28602193-1DDB0025-DD25-4FFF-AF4F-DCD4B30A3B62Q29039090-AAD68A87-EA18-41BA-B4EE-BFD3D3A8D55AQ29616779-F6F1A402-B231-433E-B802-680067B7AB34Q30736359-1CF8C00B-BCA6-4489-95D6-E5F81B33D98BQ30941414-DE4C3218-952F-4ECD-8B6E-F51F00981088Q31115332-7BB0FCF8-CFAA-4A97-97E9-8CAFA71D853AQ31125909-AA494729-343F-46B9-8810-CADB030AB5BBQ31144187-8254C57D-A638-409D-9F78-8FDA31E4FE64Q33489588-F1D56D3C-2BDE-47F9-84D6-A5FD33469DF2Q33515828-FAD8CF4B-90DD-4E73-97C0-EF314ECDD78AQ33524781-C4C78C34-5CB0-4AC7-B958-02D7B19774FAQ33588666-63F0AA9A-0956-4402-BE25-22CA3EF4CDE0Q33607376-87D776E0-3D38-4ECB-894F-8A0904710423Q33637896-76696E78-0228-45EA-834C-BE3EF7396AD8Q33680236-A4C781E3-DF81-484C-A052-2261F11180EEQ33686443-47DFE4D6-42AE-4FBB-ACE4-628AE6A4A47AQ33719123-CC4CDB76-2769-4677-B3F3-B629C00783DDQ33753441-3E36969B-16FA-4E87-84F4-B7ACCC44B162Q33811587-4999C5BF-B855-48E9-8639-212F09E12732Q33814333-693DA97D-CE36-4B11-881A-28215F914FBEQ33897405-82BF4937-2AAA-4964-84F9-4EC09115F8FEQ33907628-1943AADC-7334-4ECD-9D8D-EBD3E7DD44A4Q33951245-F221471D-69A0-4C07-AABD-4E8F1AA13BD2Q33952974-74CB333B-BEAA-4B94-B24A-A71735518BEB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
gotara zanistî
@ku-latn
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Telomerase and cancer therapeutics.
@en
Telomerase and cancer therapeutics.
@nl
type
label
Telomerase and cancer therapeutics.
@en
Telomerase and cancer therapeutics.
@nl
prefLabel
Telomerase and cancer therapeutics.
@en
Telomerase and cancer therapeutics.
@nl
P356
P1476
Telomerase and cancer therapeutics.
@en
P2093
Calvin B Harley
P2888
P304
P356
10.1038/NRC2275
P407
P577
2008-03-01T00:00:00Z